Legal Investigation Into MoonLake Immunotherapeutics
The Law Offices of Frank R. Cruz has initiated a formal investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) following significant concerns regarding the company’s adherence to federal securities laws. This inquiry comes in the wake of disappointing Phase 3 trial outcomes for the company’s only therapeutic candidate, sonelokimab (SLK), which have raised questions about the company’s disclosures and marketing practices. Investors who believe they have suffered financial losses related to MoonLake are being encouraged to reach out to the law firm for potential legal recourse.
Disappointing Trial Results Trigger Stock Collapse
On September 28, 2025, MoonLake disclosed that sonelokimab did not achieve the expected efficacy results in its Phase 3 trials, underperforming significantly against a competitor’s product, bimekizumab from Union Chimique Belge. Prior to this announcement, the company had consistently touted the advantages of its nanobody technology, suggesting that it offered superior benefits over traditional monoclonal antibodies. However, the revelation that SLK targeted similar biological pathways without any distinct advantages has led to allegations that the company failed to provide full transparency about its drug’s performance.
This news had an immediate and drastic impact on the company’s stock value, which plummeted by nearly 90% the following day, closing at $6.24 per share. This steep decline has left many investors feeling misled and financially harmed, prompting the Law Offices of Frank R. Cruz to step in and explore potential claims for recovery.
How to Get Involved in the Investigation
Investors who purchased shares of MoonLake Immunotherapeutics and believe they may have pertinent information related to this investigation are encouraged to reach out to the Law Offices of Frank R. Cruz. The firm is actively seeking to gather insights and evidence to support potential claims against the company. Interested parties can contact the firm directly via telephone or email, providing their contact details and information about their investments to facilitate the process.
The investigation is ongoing, and updates will be shared as new information becomes available. Investors are advised to exercise caution and seek independent financial advice regarding their positions in MoonLake as the situation unfolds.
Related
